Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge

Table 2 Information of envelopes used for assays

Env ID	Clade	Location	Mode of transmission	Length of infection	Mo/yr isolated	Corecepter
Du172.17	C	South Africa	M-F	12 weeks	Nov-98	R5
ZM214M.PL15	C	Zambia	F-M	<13 weeks	Jul-03	R5
CAP210.2.00.E8	C	South Africa	M-F	5 weeks	May-05	R5
CHN19	C	China				R5
HIV16936-2 EF117270	C	India	F-M	1 week	Nov-00	R5
Q168.ENV.B23	A	Kenya	M-F	1 week		R5
Q461.ENV.C2	A	Kenya	M-F	4 weeks		R5
HIV env 6235 clone 3	B	USA	M-M	6 weeks	Mar-95	R5
PVO clone 4	B	Italy	M-M	4 weeks	Jan-96	R5
pRHPA 4259 clone7	B	USA	M-F	< weeks	Dec-00	R5
pTHRO4156 clone 18	B	USA	M-M	1 week	Aug-00	R5
SC 422661.8	B	Trinidad	F-M	4 weeks	Jan-95	R5
SF162	B	USA				R5
93TH975-15	E	Haiti	F-M	<18 weeks	Jan-93	R5

Primary envelopes from various clade was chosen based to have a diversity of locations and mode of mocusal transmission. Envelopes were used to test the presence of binding and neutralizing antibodies elicited by vaccination of consensus vaccines in non-human primates. SF162 was included because it is the challenge virus envelope.

ISSN: 1743-422X